Aspen Neuroscience, a clinical-stage regenerative medicine biotechnology company, priced its initial public offering at US$15.00 per share. The company is offering 9,375,000 shares of common stock. Gross proceeds are expected to reach approximately US$140.6 million before underwriting discounts and commissions.
Trading and closing
Shares are expected to begin trading on the Nasdaq Global Select Market on October 30, 2026. They will trade under the ticker symbol ASPE. The offering is expected to close on November 2, 2026, subject to customary conditions.
Company focus
Aspen develops autologous cell therapies for Parkinson’s disease. Its lead product candidate is called sasineprocel. It is an investigational single-dose therapy based on autologous induced pluripotent stem cells.
Underwriters
Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co. are acting as joint bookrunning managers. Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares. All shares in the offering are being sold by Aspen.
The registration statement became effective on October 29, 2026. Copies of the final prospectus can be requested from the joint bookrunning managers. The offering remains subject to customary closing conditions.